Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis

Premkumar Christadoss, Regina Henderson, Steve Keve

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Myasthenia gravis (MG) is an autoimmune neuromuscular disease, characterized by muscle weakness and electrophysiological abnormality. No treatment which would reliably induce permanent clinical remission of MG is yet available. The therapeutic efficacy and toxic effect of daunomvcin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression.

Original languageEnglish (US)
Pages (from-to)246-255
Number of pages10
JournalClinical Immunology and Immunopathology
Volume59
Issue number2
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Autoimmune Experimental Myasthenia Gravis
Daunorubicin
Myasthenia Gravis
Muscle Weakness
Neuromuscular Diseases
Poisons
Immunosuppression
Autoimmune Diseases
Therapeutics
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis. / Christadoss, Premkumar; Henderson, Regina; Keve, Steve.

In: Clinical Immunology and Immunopathology, Vol. 59, No. 2, 1991, p. 246-255.

Research output: Contribution to journalArticle

Christadoss, Premkumar ; Henderson, Regina ; Keve, Steve. / Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis. In: Clinical Immunology and Immunopathology. 1991 ; Vol. 59, No. 2. pp. 246-255.
@article{0588a878418d4f17bf39434336a62b87,
title = "Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis",
abstract = "Myasthenia gravis (MG) is an autoimmune neuromuscular disease, characterized by muscle weakness and electrophysiological abnormality. No treatment which would reliably induce permanent clinical remission of MG is yet available. The therapeutic efficacy and toxic effect of daunomvcin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression.",
author = "Premkumar Christadoss and Regina Henderson and Steve Keve",
year = "1991",
doi = "10.1016/0090-1229(91)90022-3",
language = "English (US)",
volume = "59",
pages = "246--255",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis

AU - Christadoss, Premkumar

AU - Henderson, Regina

AU - Keve, Steve

PY - 1991

Y1 - 1991

N2 - Myasthenia gravis (MG) is an autoimmune neuromuscular disease, characterized by muscle weakness and electrophysiological abnormality. No treatment which would reliably induce permanent clinical remission of MG is yet available. The therapeutic efficacy and toxic effect of daunomvcin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression.

AB - Myasthenia gravis (MG) is an autoimmune neuromuscular disease, characterized by muscle weakness and electrophysiological abnormality. No treatment which would reliably induce permanent clinical remission of MG is yet available. The therapeutic efficacy and toxic effect of daunomvcin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression.

UR - http://www.scopus.com/inward/record.url?scp=0025859317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025859317&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(91)90022-3

DO - 10.1016/0090-1229(91)90022-3

M3 - Article

C2 - 2009643

AN - SCOPUS:0025859317

VL - 59

SP - 246

EP - 255

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -